Osivax announces clinical and preclinical vaccine data presentations

• Influenza vaccine candidate OVX836 safety profile and efficacy signals from Phase 2a dose-optimization study to be presented at UIV 2022
• Preclinical proof of cross-protection against SARS-COV-2 with OVX033 in hamster challenge model to be presented at Options XI
• Additional results on the synergy of co-administering T-cell based vaccine candidate OVX836 with traditional antibody-based flu vaccines will be presented in a poster session during Options XI

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced upcoming oral presentations at the Universal Influenza Vaccines (UIV) 2022 event held September 5-7 in Oxford, UK and the Options XI for the Control of Influenza conference, held September 26-29 in Belfast, UK. Osivax’ Chief Business Development Officer, Delphine Guyon-Gellin, will present the most recent clinical and preclinical data for the company’s lead programs, OVX836, a broad-spectrum influenza vaccine, and OVX033 a broad-spectrum coronavirus vaccine. Additionally, two poster presentations providing further clinical and preclinical data for OVX836 will be presented at Options XI.

Read the press release